Table 2 Univariate and multivariate analyses for PFI and OS in patients with stage II–III CCR in cohort 1.
Variable | Progression-free interval (PFI) | Overall survival (OS) | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis (n = 122) | Univariate analysis | Multivariate analysis (n = 222) | |||||
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
CINSARC classification (C1/C2) | 1.87 (1.11–3.16) | 1.68 × 10−2 | 4.55 (1.74–13.87) | 1.54 × 10−3 | 2.45 (1.31–4.59) | 3.73 × 10−3 | 3.15 (1.33–8.93) | 7.82 × 10−3 |
TNM (II/III) | 1.68 (1.04–2.71) | 3.33 × 10−2 | 1.01 (0.45–2.33) | 9.89 × 10−1 | 2.38 (1.37–4.15) | 1.54 × 10−3 | 2.14 (1.02–4.65) | 4.33 × 10−2 |
CMS (1/2/3/4) | NA | 3.32 × 10−2 | 0.60 (0.40–0.88) | 9.47 × 10−3 | NA | 1.34 × 10−1 | NA | NA |
MMR status (MSI/MSS) | 3.31 (1.03–10.66) | 3.34 × 10−2 | 2.39 (0.69–12.53) | 1.85 × 10–1 | 91138956.25 (0–INF) | 1.09 × 10−2 | 16.49 (2.30–2093.39) | 1.07 × 10−3 |
VELIPI (absence/presence) | 3.75 (1.58–8.89) | 1.34 × 10−3 | 1.59 (0.58–4.99) | 3.81 × 10−1 | 2.11 (0.9–4.97) | 8 × 10−2 | NA | NA |
Lymph nodes examined (<12≥) | 0.94 (0.4–2.18) | 8.85 × 10−1 | NA | NA | 1.76 (0.86–3.63) | 1.19 × 10–1 | NA | NA |
